title: Structure-activity relationships of analogues of NF449 confirm NF449 as the most potent and selective known P2X1 receptor antagonist.
abstract: NF449 [4,4',4",4"'-(carbonylbis(imino-5,1,3-benzenetriyl-bis(carbonylimino)))tetrakisbenzene-1,3-disulfonic acid-octasodiumsalt)] was recently described to inhibit recombinant rP2X(1) receptors (Naunyn Schmiedeberg's Arch. Pharmacol. 364 (2001) 285). The purpose of this study was to examine structure-activity-relationships at P2 receptors of a series of NF449 analogues. Thus, compounds containing various arylaminemono-, di-, or trisulfonic acids and a replacement of the central urea bridge were synthesized. NF449 displayed a pIC(50) at P2X(1) receptors (rat vas deferens) of 6.31 +/- 0.04 being at least 19-fold more potent at P2X(1) than at P2X(3), P2Y(1), P2Y(2), or P2Y(11). Any deletion or change of position of sulfonic acid groups or replacing the central urea bond by the bisamide of terephthalic acid reduced the potency at P2X(1) by at least 90%. All compounds were very weak antagonists at P2Y(2) or P2Y(11) receptors (pIC(50) < 4.5). In conclusion, NF449 remains the most potent and selective P2X(1) antagonist known. Potential lead compounds among the suramin class for P2X(3) (16d) and P2Y(1) (16a) receptors were identified.
authors.affiliation: Pharmaceutical Institute, University of Bonn, An der Immenburg 4, 53121 Bonn, Germany. kassack@uni-bonn.de
authors.forename: Matthias U
authors.initials: MU
authors.lastname: Kassack
authors.forename: Kirsten
authors.initials: K
authors.lastname: Braun
authors.forename: Matthias
authors.initials: M
authors.lastname: Ganso
authors.forename: Heiko
authors.initials: H
authors.lastname: Ullmann
authors.forename: Peter
authors.initials: P
authors.lastname: Nickel
authors.forename: Barbara
authors.initials: B
authors.lastname: Böing
authors.forename: Gregor
authors.initials: G
authors.lastname: Müller
authors.forename: Günter
authors.initials: G
authors.lastname: Lambrecht
mesh_terms: D000255:Adenosine Triphosphate / Q000378:metabolism; D000818:Animals; D001557:Benzenesulfonates / Q000737:chemistry / Q000494:pharmacology*; D002460:Cell Line; D004305:Dose-Response Relationship, Drug; D006168:Guinea Pigs; D006801:Humans; D007082:Ileum / Q000187:drug effects / Q000378:metabolism; D007928:Lethal Dose 50; D008297:Male; D058919:Purinergic P2 Receptor Antagonists; D051381:Rats; D018048:Receptors, Purinergic P2 / Q000378:metabolism; D058469:Receptors, Purinergic P2X; D013329:Structure-Activity Relationship; D013498:Suramin / Q000031:analogs & derivatives / Q000494:pharmacology; D014544:Uridine Triphosphate / Q000378:metabolism; D014649:Vas Deferens / Q000187:drug effects / Q000378:metabolism
chemical_list: C110258:4,4,',4'',4'''-(carbonylbis(imino-5,1,3-benzenetriylbis(carbonylimino)))tetrakis(benzene-1,3-disulfonate); D001557:Benzenesulfonates; D058919:Purinergic P2 Receptor Antagonists; D018048:Receptors, Purinergic P2; D058469:Receptors, Purinergic P2X; D013498:Suramin; D000255:Adenosine Triphosphate; D014544:Uridine Triphosphate